Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 28M | 27M | 11M | 7M | 5M |
| Gross Profit | 17M | 16M | 4M | 4M | -4M |
| Operating Income | -47M | -46M | -35M | -16M | -7M |
| EBITDA | -40M | -44M | -36M | -16M | -6M |
| Net Income | -48M | -48M | -39M | -18M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.001
+0.00% today
1Y Change
-99.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telesis Bio, Inc. (TBIO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +0.3%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue +0.3%, EPS +3.6%, free cash flow +15.1% with operating margin -169.2% and ROIC -72.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines TBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBIO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TBIO Max Drawdown
-99.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TBIO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.8M
-26.9% YoY
FY Net Income
-$8.3M
+53.9% YoY
Free Cash Flow
-$6.5M
+58.5% YoY
Revenue Growth
+0.3%
EPS Growth
+3.6%
Gross Margin
61.6%
Net Margin
-173.5%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 28M | 27M | 11M | 7M | 5M |
| Gross Profit | 17M | 16M | 4M | 4M | -4M |
| Operating Income | -47M | -46M | -35M | -16M | -7M |
| EBITDA | -40M | -44M | -36M | -16M | -6M |
| Net Income | -48M | -48M | -39M | -18M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 30M | 83M | 13M | 29M |
| Total Assets | 70M | 81M | 116M | 27M | 39M |
| Total Liabilities | 41M | 35M | 25M | 52M | 46M |
| Shareholder Equity | 30M | 47M | 91M | -25M | -8M |
| Total Debt | 34M | 21M | 17M | 8M | 5M |
| Net Debt | 33M | -9M | -65M | -5M | -24M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+58.5% YoY
Capital Expenditures
79K
+61.3% YoY
Free Cash Flow
6M
+58.5% YoY
Key ratios
Gross Margin
61.6%
Operating Margin
-169.2%
Net Margin
-173.5%
ROE
-125.4%
Debt / Equity
1.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.